Drug
Fluoruracil
Fluoruracil is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
2
50%
Ph phase_2
2
50%
Phase Distribution
0
Early Stage
2
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
2(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(1)
Other(2)
Detailed Status
unknown2
Completed1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 22 (50.0%)
Phase 32 (50.0%)
Trials by Status
completed125%
recruiting125%
unknown250%
Recent Activity
1 active trials
Showing 4 of 4
recruitingphase_3
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
NCT06205485
completedphase_2
Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients
NCT04072198
unknownphase_3
Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC
NCT02339116
unknownphase_2
Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.
NCT02506777
Clinical Trials (4)
Showing 4 of 4 trials
NCT06205485Phase 3
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
NCT04072198Phase 2
Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients
NCT02339116Phase 3
Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC
NCT02506777Phase 2
Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4